NO954175L - Anvendelse av vWF-inneholdende konsentrater som kombinasjonsterapi ved antitrombotika og fibrinolytika terapi - Google Patents

Anvendelse av vWF-inneholdende konsentrater som kombinasjonsterapi ved antitrombotika og fibrinolytika terapi

Info

Publication number
NO954175L
NO954175L NO954175A NO954175A NO954175L NO 954175 L NO954175 L NO 954175L NO 954175 A NO954175 A NO 954175A NO 954175 A NO954175 A NO 954175A NO 954175 L NO954175 L NO 954175L
Authority
NO
Norway
Prior art keywords
therapy
vwf
antithrombotic
fibrinolytic
containing concentrates
Prior art date
Application number
NO954175A
Other languages
English (en)
Other versions
NO954175D0 (no
Inventor
Martin Reers
Gerhard Dickneite
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of NO954175D0 publication Critical patent/NO954175D0/no
Publication of NO954175L publication Critical patent/NO954175L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Administrering av Willebrand faktor (vWF)-inneholdende medikamenter ved : terapeutisk anvendelse av blodantikoagulerende midler alene, eller i forbindelse med fibrinolytika er beskrevet. Administreringen kan foregå både samtidig og også etter den antikoagulerende og lyserende behandlingen for redusering av blødningsrisikoen i pasienter. Det er beskrevet et terapiprinsipp som separerer den ønskede virkningen til antikoagulasjon og/eller fibrinolyse fra uønskede bivirkninger ved blødningstilbøyeligheter i løpet av terapi.
NO954175A 1994-10-20 1995-10-19 Anvendelse av vWF-inneholdende konsentrater som kombinasjonsterapi ved antitrombotika og fibrinolytika terapi NO954175L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4437544A DE4437544A1 (de) 1994-10-20 1994-10-20 Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika

Publications (2)

Publication Number Publication Date
NO954175D0 NO954175D0 (no) 1995-10-19
NO954175L true NO954175L (no) 1996-04-22

Family

ID=6531287

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954175A NO954175L (no) 1994-10-20 1995-10-19 Anvendelse av vWF-inneholdende konsentrater som kombinasjonsterapi ved antitrombotika og fibrinolytika terapi

Country Status (20)

Country Link
US (1) US5571784A (no)
EP (1) EP0713881A3 (no)
JP (1) JPH08208504A (no)
KR (1) KR960013383A (no)
CN (1) CN1128168A (no)
AU (1) AU708670B2 (no)
CA (1) CA2160975A1 (no)
CZ (1) CZ287878B6 (no)
DE (1) DE4437544A1 (no)
FI (1) FI954964L (no)
HR (1) HRP950525A2 (no)
HU (1) HU219595B (no)
IL (1) IL115652A (no)
NO (1) NO954175L (no)
NZ (1) NZ280274A (no)
PL (1) PL183182B1 (no)
SK (1) SK129695A3 (no)
TW (1) TW398977B (no)
UY (1) UY24063A1 (no)
ZA (1) ZA958838B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
AT405485B (de) * 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
AT409335B (de) * 1998-11-10 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
JP5914363B2 (ja) * 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
TWI580423B (zh) * 2013-12-24 2017-05-01 財團法人工業技術研究院 緩解或治療痛風之醫藥組合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4774323A (en) * 1987-06-29 1988-09-27 Rorer Pharmaceutical Corporation Purification of von Willebrand Factor solutions using gel permeation chromatography
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
GB8823480D0 (en) * 1988-10-06 1988-11-16 Ciba Geigy Ag Antidote
US5204323B1 (en) 1988-10-06 1995-07-18 Ciba Geigy Corp Hirudin antidotal compositions and methods
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
DE4115453A1 (de) * 1991-05-11 1992-11-12 Knoll Ag Neue wirkstoffkombination
US5366869A (en) * 1991-11-08 1994-11-22 Sheldon Goldstein Multiple coagulation test device and method
DE4203965A1 (de) * 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
CA2159508A1 (en) * 1993-04-23 1994-11-10 Leonard Garfinkel Method of enhancing thrombolysis
DE4430205A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung

Also Published As

Publication number Publication date
CZ287878B6 (cs) 2001-03-14
UY24063A1 (es) 1995-10-24
NO954175D0 (no) 1995-10-19
AU708670B2 (en) 1999-08-12
FI954964A7 (fi) 1996-04-21
TW398977B (en) 2000-07-21
CZ271995A3 (en) 1996-05-15
AU3430495A (en) 1996-05-02
HUT73762A (en) 1996-09-30
IL115652A (en) 2000-08-31
US5571784A (en) 1996-11-05
HRP950525A2 (en) 1997-04-30
NZ280274A (en) 1997-01-29
KR960013383A (ko) 1996-05-22
IL115652A0 (en) 1996-01-19
FI954964L (fi) 1996-04-21
ZA958838B (en) 1996-05-13
PL311031A1 (en) 1996-04-29
DE4437544A1 (de) 1996-04-25
CN1128168A (zh) 1996-08-07
HU219595B (hu) 2001-05-28
FI954964A0 (fi) 1995-10-18
EP0713881A3 (de) 1996-08-21
JPH08208504A (ja) 1996-08-13
HU9503031D0 (en) 1995-12-28
EP0713881A2 (de) 1996-05-29
PL183182B1 (pl) 2002-06-28
SK129695A3 (en) 1996-10-02
CA2160975A1 (en) 1996-04-21

Similar Documents

Publication Publication Date Title
Kramer et al. Arteriovenous haemofiltration: a new and simple method for treatment of over-hydrated patients resistant to diuretics
WO2001049236A3 (en) Method and system for treating cardiac arrest
ATE153856T1 (de) Zusammensetzung zur stimulierung des immunsystems
SE9702860L (sv) Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod
IL76119A0 (en) Initiating reperfusion treatment when heart attack symptoms are present
DE69722401D1 (de) Kombinationen von vasopressin und adrenergischen wirkstoffen zur behandlung des plötzlichen herztods
EP0246715A3 (en) Apparatus for the safe delivery of a beneficial agent to a patient
ATE114118T1 (de) System zur verabreichung von medikamenten durch ein zweistufiges iontophoresenverfahren.
IE790952L (en) Acyl-carnitine solutions for haemodialysis
SE8903914D0 (sv) Oral composition for the treatment of inflammatory bowel diseases
AU4553700A (en) Substitution infusion fluid and citrate anticoagulation
DE69734450D1 (de) Photopherese-behandlung von hcv-infektionen
DE3372711D1 (en) A tube set intended for extracorporeal treatment of blood and similar perishable liquids
BR9713653B1 (pt) composiÇço farmacÊutica, mÉtodo para preparar uma composiÇço farmacÊutica, e, uso de pirofosfato fÉrrico.
Yokoyama et al. Comparative study of biocompatibility between the open circuit and closed circuit in cardiopulmonary bypass.
Teoh et al. Blood conservation with membrane oxygenators and dipyridamole
KR960013383A (ko) 항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도
DE69227042D1 (de) Verfahren und zusammensetzungen zur verminderung von blutverlust
Takanashi et al. Reduction of myocardial infarct size in swine: a comparative study of intraaortic balloon pumping and transapical left ventricular bypass
Lewis et al. Severe haemoptysis associated with viral tracheitis
Schneider et al. Safety of intraaortic balloon pumping. I. Biochemic and hematologic values influenced by use of balloon
DE3650368D1 (de) Verwendung von Depogen zur Behandlung von eingeschränktem Blutkreislauf.
RU1805971C (ru) Способ лечени гнойно-септических заболеваний
Pinterova et al. The effect of bopindolol on lipids and platelet aggregation
Tatsumi et al. Long–Term Respiratory Assistance Using a Right Ventricular Assist Device System and a Membrane Oxygenator

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application